AQUAMEPHYTON Drug Patent Profile
✉ Email this page to a colleague
When do Aquamephyton patents expire, and when can generic versions of Aquamephyton launch?
Aquamephyton is a drug marketed by Pai Holdings Pharm and is included in one NDA.
The generic ingredient in AQUAMEPHYTON is phytonadione. Thirty-one suppliers are listed for this compound. Additional details are available on the phytonadione profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aquamephyton
A generic version of AQUAMEPHYTON was approved as phytonadione by AMNEAL PHARMS CO on May 11th, 2018.
US Patents and Regulatory Information for AQUAMEPHYTON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pai Holdings Pharm | AQUAMEPHYTON | phytonadione | INJECTABLE;INJECTION | 012223-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pai Holdings Pharm | AQUAMEPHYTON | phytonadione | INJECTABLE;INJECTION | 012223-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
